Catalog No.
DHE43401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, NKAT2b, KIR2DL3, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158 antigen-like family member B2, MHC class I NK cell receptor, KIR-023GB, Killer inhibitory receptor cl 2-3, p58 NK receptor CL-6, CD158b2, Killer cell immunoglobulin-like receptor 2DL3, Natural killer-associated transcript 2, CD158B2, KIRCL23, NKAT-2, NKAT2a, NKAT2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P43626 & P43627 & P43628
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-986015, IPH2102, CAS: 1000676-41-4
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome, PMID: 30001986
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies, PMID: 29707140
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies, PMID: 32601377
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals, PMID: 28723950
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma, PMID: 30828910
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies, PMID: 24326534
How to outsmart NK cell tolerance, PMID: 26405590
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy, PMID: 24701370
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets., PMID:38955423
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab., PMID:38185735
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy., PMID:38155060
Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition., PMID:35174079
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck., PMID:34667025
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies., PMID:32601377
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma., PMID:30828910
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome., PMID:30001986
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies., PMID:29707140
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals., PMID:28723950
How to outsmart NK cell tolerance., PMID:26405590
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy., PMID:24701370
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies., PMID:24326534
For research use only. Not for human or drug use.
